Differential tumorigenic potential and matriptase activation between PDGF B versus PDGF D in prostate cancer

Molecular Cancer Research

Volumn 10, Issue 8, 2012, Pages 1087-1097

  Najy, Abdo J ^a   Won, Joshua J ^a   Movilla, Lisa S ^a   Kim, Hyeong Reh C ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIPTASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR D; SHORT HAIRPIN RNA; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CANCER GROWTH; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME REGULATION; ENZYME RELEASE; EPITHELIUM CELL; GENETIC ENGINEERING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOKINES; MALE; MICE; MICE, SCID; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASM INVASIVENESS; PLATELET-DERIVED GROWTH FACTOR; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-SIS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION;

EID: 84865304366     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0071     Document Type: Article

References (47)

1. Betsholtz C, Karlsson L, Lindahl P. Developmental roles of platelet-derived growth factors. Bioessays 2001;23:494-507.
2. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008;22:1276-312.
3. Heldin CH, Ostman A, Ronnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta 1998;1378:F79-113.
4. Karvinen H, Rutanen J, Leppanen O, Lach R, Levonen AL, Eriksson U, et al. PDGF-C and -D and their receptors PDGFR-alpha and PDGFR-beta in atherosclerotic human arteries. Eur J Clin Invest 2009;39:320-7.
5. Borkham-Kamphorst E, van Roeyen CR, Ostendorf T, Floege J, Gressner AM, Weiskirchen R. Pro-fibrogenic potential of PDGF-D in liver fibrosis. J Hepatol 2007;46:1064-74.
6. Fredriksson L, Li H, Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 2004;15:197-204.
7. Reigstad LJ, Varhaug JE, Lillehaug JR. Structural and functional specificities of PDGF-C and PDGF-D, the novel members of the platelet-derived growth factors family. FEBS J 2005;272:5723-41.
8. Hurst NJ Jr., Najy AJ, Ustach CV, Movilla L, Kim HR. Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progression. Biochem J 2012;441:909-18.
9. Ustach CV, Huang W, Conley-LaComb MK, Lin CY, Che M, Abrams J, et al. A novel signaling axis of matriptase/PDGF-D/ss-PDGFR in human prostate cancer. Cancer Res 2010;70:9631-40.
10. Yu J, Ustach C, Kim HR. Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol 2003;36:49-59.
11. Wang Z, Ahmad A, Li Y, Kong D, Azmi AS, Banerjee S, et al. Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta 2010;1806:122-30.
12. Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 2002;62:3729-35.
13. Murata T, Mizushima H, Chinen I, Moribe H, Yagi S, Hoffman RM, et al. HB-EGF and PDGF mediate reciprocal interactions of carcinoma cells with cancer-associated fibroblasts to support progression of uterine cervical cancers. Cancer Res 2011;71:6633-42.
14. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36.
15. Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R, et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 2003;95:458-70.
16. Ko YJ, Small EJ, Kabbinavar F, Chachoua A, Taneja S, Reese D, et al. A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res 2001;7:800-5.
17. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer cell 2002;1:203-9.
18. Conley-LaComb MK, Huang W, Wang S, Shi D, Jung YS, Najy A, et al. PTEN regulates PDGF ligand switch for beta-PDGFR signaling in prostate cancer. Am J Pathol 2012;180:1017-27.
19. List K. Matriptase: a culprit in cancer? Future Oncol (London, England) 2009;5:97-104.
20. Berquin IM, Min Y, Wu R, Wu J, Perry D, Cline JM, et al. Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest 2007;117:1866-75.
21. Wang S, Wu J, Suburu J, GuZ, Cai J, Axanova LS, et al. Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer. Carcinogenesis 2012;33:404-12.
22. Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N, Narayan P. Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim 1995;31:14-24.
23. Ustach CV, Taube ME, Hurst NJ Jr, Bhagat S, Bonfil RD, Cher ML, et al. A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progression. Cancer Res 2004;64:1722-9.
24. Najy AJ, Day KC, Day ML. ADAM15 supports prostate cancer metastasis by modulating tumor cell-endothelial cell interaction. Cancer Res 2008;68:1092-9.
25. Bronzert DA, Pantazis P, Antoniades HN, Kasid A, Davidson N, Dickson RB, et al. Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci U S A 1987;84:5763-7.
26. Johnsson A, Heldin CH, Wasteson A, Westermark B, Deuel TF, Huang JS, et al. The c-sis gene encodes a precursor of the B chain of platelet-derived growth factor. EMBO J 1984;3:921-8.
27. Kaetzel DM Jr, Morgan D 3rd, Reid JDt, Fenstermaker RA. Site-directed mutagenesis of the N-linked glycosylation site in platelet-derived growth factor B-chain results in diminished intracellular retention. Biochim Biophys Acta 1996;1298:250-60.
28. Rozengurt E, Stroobant P, Waterfield MD, Deuel TF, Keehan M. Platelet-derived growth factor elicits cyclic AMP accumulation in Swiss 3T3 cells: role of prostaglandin production. Cell 1983;34:265-72.
29. Ouwens DM, de Ruiter ND, van der Zon GC, Carter AP, Schouten J, van der Burgt C, et al. Growth factors can activate ATF2 via a two-step mechanism: phosphorylation of Thr71 through the Ras-MEK-ERK pathway and of Thr69 through RalGDS-Src-p38. EMBO J 2002;21:3782-93.
30. LaRochelle WJ, Jeffers M, McDonald WF, Chillakuru RA, Giese NA, Lokker NA, et al. PDGF-D, a new protease-activated growth factor. Nat Cell Biol 2001;3:517-21.
31. Lin CY, Tseng IC, Chou FP, Su SF, Chen YW, Johnson MD, et al. Zymogen activation, inhibition, and ectodomain shedding of matriptase. Front Biosci 2008;13:621-35.
32. Uhland K. Matriptase and its putative role in cancer. Cell Mol Life Sci 2006;63:2968-78.
33. Uutela M, Wirzenius M, Paavonen K, Rajantie I, He Y, Karpanen T, et al. PDGF-D induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis. Blood 2004;104:3198-204.
34. Owen KA, Qiu D, Alves J, Schumacher AM, Kilpatrick LM, Li J, et al. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA. Biochem J 2010;426:219-28.
35. Li H, Fredriksson L, Li X, Eriksson U. PDGF-D is a potent transforming and angiogenic growth factor. Oncogene 2003;22:1501-10.
36. Huang W, Fridman Y, Bonfil RD, Ustach CV, Conley-Lacomb MK, Wiesner C, et al. A novel function for platelet-derived growth factor D: induction of osteoclastic differentiation for intraosseous tumor growth. Oncogene 2011. Dec 12. [Epub ahead of print].
37. Su YC, Han J, Xu S, Cobb M, Skolnik EY. NIK is a new Ste20-related kinase that binds NCK and MEKK1 and activates the SAPK/JNK cascade via a conserved regulatory domain. EMBO J 1997;16:1279-90.
38. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
39. Wang Z, Kong D, Banerjee S, Li Y, Adsay NV, Abbruzzese J, et al. Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling. Cancer Res 2007;67:11377-85.
40. Xu L, Tong R, Cochran DM, Jain RK. Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res 2005;65:5711-9.
41. Zhao L, Zhang C, Liao G, Long J. RNAi-mediated inhibition of PDGF-D leads to decreased cell growth, invasion and angiogenesis in the SGC-7901 gastric cancer xenograft model. Cancer Biol Ther 2010;9:42-8.
42. Liu J, Liao S, Huang Y, Samuel R, Shi T, Naxerova K, et al. PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer. Clin Cancer Res 2011;17:3638-48.
43. List K, Bugge TH, Szabo R. Matriptase: potent proteolysis on the cell surface. Mol Med (Cambridge, Mass) 2006;12:1-7.
44. Bugge TH, List K, Szabo R. Matriptase-dependent cell surface proteolysis in epithelial development and pathogenesis. Front Biosci 2007;12:5060-70.
45. Wu SR, Cheng TS, Chen WC, Shyu HY, Ko CJ, Huang HP, et al. Matriptase is involved in ErbB-2-induced prostate cancer cell invasion. Am J Pathol 2010;177:3145-58.
46. Rao K, Goodin S, Levitt MJ, Dave N, Shih WJ, Lin Y, et al. A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate 2005;62:115-22.
47. Najy AJ, Jung YS, Won JJ, Conley-Lacomb MK, Saliganan A, Kim CJ, et al. Cediranib inhibits both the intraosseous growth of PDGF D-Positive prostate cancer cells and the associated bone reaction. Prostate 2011. Dec 27. [Epub ahead of print].